WHO ICTRP trial
A Phase 3 Study of Ravulizumab to Protect Patients with CKD from CSA-AKI and…
JPRN-jRCT2031230020 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031230020 |
|---|---|
| Public title | A Phase 3 Study of Ravulizumab to Protect Patients with CKD from CSA-AKI and MAKE |
| Scientific title | RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study - ARTEMIS |
| Primary sponsor | Yokosawa Jun |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Japan;Australia;Japan;Brazil;Japan;Canada;Japan;Germany;Japan;Israel;Japan;Italy;Japan;Korea;Japan;Poland;Japan;Spain;Japan;Taiwan;Japan;Turkey;Japan;United Kingdom;Japan;United States;Japan |
| Conditions | Chronic Kidney Disease CKD Cardiac Disease Cardiopulmonary Bypass CSA-AKI;CSA-AKI |
| Interventions | Participants will receive a single weight-based dose of ravulizumab, via intravenous infusion, 1 to 7 days prior to surgery as below dosage regimen; In cae Patient Body Weight (kg) is 30 to 40: 2700mg, In cae Patient Body Weight (kg) is 40… |
| Registration date | Apr 16, 2023 |
| Target size | 36 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: